Cullinan Therapeutics (CGEM) Operating Expenses (2020 - 2026)

Cullinan Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $53.7 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 2.36% year-over-year to $53.7 million in Q1 2026; TTM through Mar 2026 was $240.3 million, a 15.04% increase from a year earlier, with the FY2025 full-year figure at $241.6 million, up 22.71% from the prior year.
• Operating Expenses slipped to $53.7 million in Q1 2026 per CGEM's latest filing, from $55.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $75.8 million in Q2 2025 and bottomed at $29.8 million in Q3 2022.
• The 5-year median for Operating Expenses is $48.9 million (2024), against an average of $47.9 million.
• Across the five-year window, Operating Expenses jumped 123.48% in 2022 and sank 31.5% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $32.6 million in 2022, then jumped by 39.49% to $45.5 million in 2023, then increased by 21.02% to $55.0 million in 2024, then advanced by 0.38% to $55.3 million in 2025, then decreased by 2.83% to $53.7 million in 2026.
• Per Business Quant, the three latest CGEM Operating Expenses figures stand at $53.7 million (Q1 2026), $55.3 million (Q4 2025), and $55.6 million (Q3 2025).